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Background: Aside from their cholesterol-lowering effects statins are known to have a range of other
‘pleiotropic’ effects. We present an overview of the basic science behind these effects and then review
clinical trials and the current role of statins relevant to modern surgical practice.
Methods: A systematic review of the literature was performed using the keywords surgery and the MeSH
term for statins. All clinical studies relating to statin use in surgical patients were evaluated. An overview
of the literature on statin use and cardiac outcomes was performed.
Conclusions: Statins are safe and have a wide range of pleiotropic effects relevant to surgical practice.
Strongest evidence for their clinical use comes in primary cardiac risk reduction in many types of
vascular surgery. There is a large body of evidence showing their beneﬁt perioperatively in high-risk
vascular and cardiac surgery but the picture is less clear for low-risk patients. Further studies are needed
to evaluate exact dosage regimes and timing of administration. Novel uses of their anti-inﬂammatory
properties in sepsis and vasomotor properties in subarachnoid haemorrhage are being further investi-
gated by randomised trials.
 2009 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Since approval for the treatment of dyslipidaemia in 1987, sta-
tins or 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors have
become of the most commonly prescribed medications.1 Most
evidence for long-term statin use comes from trials aiming to
reduce adverse cardiac events. These have shown beneﬁt in
patients for secondary cardiovascular risk reduction regardless of
awide variety of variables including baseline cholesterol levels.2,3 It
is now well established that statins have a wide range of ‘pleio-
tropic effects’ independent of cholesterol-lowering.4 We reviewed
the current knowledge base on statins from a surgical perspective.
2. Methods
A keyword based database search for studies evaluating
outcomes of statin treatment relevant to surgical areas was con-
ducted. This was done by evaluating articles found with the
keyword surgery and the MeSH term for statins – hydrox-
ymethylglutaryl-CoA reductase inhibitors. Meta-analyses, rando-
mised controlled trials and systematic reviews were used in the
ﬁrst instance. Observational studies were used where meta-anal-
yses or randomised trials were unavailable or to illustrate the logic
behind the randomised trials. Case reports were not included. Anfax: þ44 (01223) 216015.
(P.D. Hayes).
Elsevier Ltd on behalf of Surgical Aoverview of the literature on statin use and cardiac outcomes was
performed.
3. Surgically relevant pleiotropic effects of statins
The non-cholesterol linked effects of statins are an area of
ongoing research.4 Of particular surgical relevance are four areas:
vasomotor effects, coagulation effects, inﬂammatory response
modulation and atherosclerotic plaque stabilisation. These are
summarised in Fig. 1.
3.1. Vasomotor effects
Statins prolong endothelial Nitric Oxide Synthase (eNOS)
activity producing vasodilatation.4,5 Animals exhibited better
coronary relaxation if treated with statins despite no difference in
cholesterol versus placebo.6 Atorvastatin improves brachial artery
ﬂow in humans following transient systemic inﬂammation after
Salmonella typhi vaccination, and, short-term administration of
pravastatin increases cerebral blood ﬂow measured by transcranial
Doppler in healthy adults.7,8
3.2. Effects on coagulation
Virchow identiﬁed vessel wall thrombogenicity, local blood ﬂow
properties and circulating haemostatic factors as key factorsssociates Ltd.
Fig. 1. Summary of some surgically relevant pleiotropic effects of Statins. NO: nitric oxide; eNOS: endothelial nitric oxide synthase; CRP: C-reactive protein; IL-10: interleukin-10;
LFA-1: leucocyte function antigen-1; LDL: low density lipoprotein.
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lipopolysaccharide (LPS) induced tissue factor expression by
endothelial cells.10,11 Statins decrease platelet aggregation inde-
pendent of levels of low density lipoprotein (LDL-C).11,12 Statins
increase tissue plasminogen activator (tPA) and inhibit plasmin-
ogen activator inhibitor (PAI)-1, thus favouring ﬁbrinolysis.10 A
systematic review concluded that ﬁbrinogen levels were affected
by statins in those patients who had high ﬁbrinogen levels to start
with (>400 mg/dl).13 It is increasingly recognised that raised levels
of ﬁbrinogen predict the severity of, and serve as a marker for
future development of peripheral arterial disease.14
3.3. Inﬂammatory response modulation
3.3.1. Acute effects of statin use
Intra-peritoneal simvastatin in rat models of acute pancreatitis
reduces levels of the pro-inﬂammatory cytokine interleukin-10.15
C-reactive protein (CRP) has a short half and is sensitive to ongoing
inﬂammation.16 The acute effect of statins on the systemic
inﬂammatory response is reﬂected by CRP reductions within 24 h
of high-dose simvastatin.17 In healthy men, pre-treatment with
simvastatin lowered increases in CRP and other inﬂammatory
markers after sepsis-induced inﬂammation by intravenous endo-
toxin (LPS).18 A rebound increase in CRP and other markers of
inﬂammation within 2 days of discontinuing atorvastatin high-
lights the importance of continuing therapy perioperatively.19
3.3.2. Chronic effects of statin use
Higher levels of CRP correlate with cardiovascular risk as well as
progression of carotid artery stenosis.16,20 In a randomised trial,
pravastatin decreased CRP levels by 16.9% (p< 0.001) over 12
weeks independent of LDL-C levels and a variety of other vari-
ables.21 Risk reduction increased in proportion to baseline CRP.21
The JUPITER trial supports the importance of the effect of statins on
CRP.22 This multicentre, randomised, placebo-controlled trial of
rosuvastatin enrolled 18,000 otherwise healthy patients with
‘normal’ LDL-C levels but a highly sensitive CRP of >2 mg/l with noobvious cause. The mean hs-CRP was signiﬁcantly lower in the
rosuvastatin treated group (p< 0.001 between groups). The
combined primary endpoint (myocardial infarction [MI], stroke,
coronary revascularisation, hospitalisation for unstable angina and
cardiovascular death) was signiﬁcantly reduced by rosuvastatin
(hazard ratio [HR] for rosuvastatin¼ 0.56; 95% conﬁdence interval
[CI]: 0.46–0.69; p< 0.00001). This correlates to a 5-year number
needed to treat (NNT) to prevent one primary endpoint of 25.22
3.4. Atherosclerotic plaque stabilisation/regression
Fatal post-operative MIs result from plaque rupture as often as
excessive oxygen demand.23 Statins dampen the inﬂammatory
atherosclerotic process, stabilising plaques.11,24 They reduce
inﬂammatory cells in coronary plaques at the vulnerable ﬁbrous
cap and also reduce LDL-C in the lipid core.24–26 There is an asso-
ciation between carotid intimal medial thickening (IMT) and
cardiovascular disease.27–32 Statins decrease mean IMT over
a period of years, with the greatest decreases being proportional to
LDL-C levels.33,34 Two years of aggressive lipid lowering with sta-
tins produced actual coronary plaque regression (a decrease in
atheroma volumes) on intravascular ultrasound.35
4. Perioperative statin use
Making use of the wide range of pleiotropic effects of statins
perioperatively to reduce cardiovascular and other risks is an area
of ongoing research. A systematic review of observational studies
demonstrated reductions in perioperative death or acute coronary
syndrome (ACS) with statin use (summary odds ratio [OR] for death
or ACS¼ 0.70; 95% CI: 0.57–0.87).36 The two randomised trials
included showed promising pooled results (summary OR for death
or ACS¼ 0.26; 95% CI: 0.07–0.99).36–38 The randomised DECREASE-
IV trial evaluated the effects of bisoprolol and ﬂuvastatin on cardiac
outcomes in ‘intermediate risk’ patients undergoing a variety of
elective non-cardiac surgery.39 The primary endpoint of cardiac
death and MI 30 days post-operatively was reduced in both
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statistical signiﬁcance in the bisoprolol group.39 There is enough
evidence to recommend perioperative statin use in high-risk
patients but insufﬁcient yet to recommend routine use for all
patients.36,40–42
4.1. Use in patients undergoing vascular surgery
Many studies using statins for perioperative risk reduction have
been in vascular surgery. Discounting papers included in the
systematic review by Kapoor et al.,36 we identiﬁed studies
regarding both cardiac and renal risk reduction in patients under-
going vascular surgery.
4.1.1. Cardiac risk reduction
Perioperative myocardial ischaemia and infarction worsens
survival.43 The DECREASE-III trial randomised 497 patients under-
going non-cardiac vascular surgery.44 Fluvastatin XL 80 mg or
placebo was administered for a median of 37 days pre-operatively
and continued for at least 1 month afterwards. All patients were on
b-blockers. Cholesterol levels fell in the statin group. Fluvastatin
produced a 9% absolute risk reduction in myocardial ischaemia
(10.9% versus 19.0%, OR¼ 0.53; 95% CI: 0.32–0.88, p¼ 0.016). The
combined endpoint of cardiovascular mortality or non-fatal MI also
reduced (4.8% versus 10.1%, OR¼ 0.48; 95% CI: 0.24–0.95,
p¼ 0.039). The NNT to prevent one excess MI was 13. Inﬂammatory
markers such as CRP and interleukin-6 were also signiﬁcantly
reduced in the statin group (p< 0.001 between groups).44
Patients who had withdrawal of statins after vascular surgery
have an increased risk for post-operative troponin release
(HR¼ 4.6; 95% CI: 2.2–9.6) and the combination of MI and cardio-
vascular death (HR¼ 7.5; 95% CI: 2.8–20.1), providing evidence for
the rebound effect discussed previously.45 A pharmaco-economic
analysis using NHS reference costs suggested that perioperative
statin therapy in vascular surgery presents the most cost effective
use of statin therapy yet described with an NNT of 15 to prevent an
adverse cardiac event.46
4.1.2. Renal protection
Statins are renoprotective in patients undergoing open
abdominal aortic aneurysm (AAA) repair.47 With no difference in
pre-operative creatinine levels and glomerular ﬁltration rates, and
after adjustment for aortic cross clamping time and blood loss,
creatinine levels are lower 30 days post-operatively in statin users
compared to non-users (102 mmol/l versus 174 mmol/l, analysis-
of-variance p< 0.01).47 Large observational cohort studies in
patients undergoing lower limb extremity bypass or AAA surgery
have shown that if kidney function deteriorated, statin use was
associated with increased odds of complete kidney function
recovery (OR¼ 2.0, 95% CI: 1.0–3.8).48 Trials with well deﬁned pre-
operative statin dosing regimes are increasingly needed to answer
interesting questions posed by observational studies.
5. Use of statins in non-cardiac vascular patients
Perioperative risks aside, statins have other surgically relevant
effects in patients with peripheral arterial disease, carotid artery
disease and aneurysmal disease.
5.1. Peripheral vascular disease
It is well established that the presence of peripheral vascular
disease alone is linked to increased rates of cardiovascular disease
and that these risks can be decreased with statins, particularly in
those with a total cholesterol of >3.5 mmol/l.3,49,50 Statins improveperipheral vascular function. Claudicants randomised to simvasta-
tin 40 mg or placebo displayed enhanced ankle-brachial pressure
index at rest and after exercise at 3 and 6 months. The pain-free
walking distance increased 90 m more (95% CI: 64–116 m,
p< 0.005) in the simvastatin group.51
5.2. Carotid artery disease
Each 10% reduction of LDL-C by statins reduces the risk of stroke
by 15.6% (95% CI: 3.7–23.6) and reduces carotid IMT by 0.73% (95%
CI: 0.27–1.19).52 Plaque stabilisation was conﬁrmed histologically
by examining plaques from carotid endarterectomy (CEA) patients
pre-treated with pravastatin compared to placebo.26 The multi-
centre, randomised SPARCL trial in patients with symptomatic
cerebrovascular disease, but without known coronary artery
disease found fewer strokes in the statin arm.53 Subgroup analysis
of those with carotid artery stenosis (mean stenosis 51%) showed
atorvastatin treated subjects had a 7% absolute reduction (34%
relative risk [RR] reduction) in the rate of stroke or transient
ischaemic attack (HR¼ 0.66; 95% CI: 0.50–0.89, p¼ 0.005) as well
as a 4% absolute reduction (56% RR reduction) in later rates of CEA
compared with placebo over 5 years (HR¼ 0.44; 95% CI: 0.24–0.79,
p¼ 0.006).54
5.3. Aneurysmal disease
Given the anti-inﬂammatory effects of statins, their role in
controlling AAA expansion has been investigated. Statin pre-
treatment decreases matrix metalloproteinase levels, which are
thought to cause proteolysis and aneurysm expansion.55,56
A recent systematic review of AAA expansion inhibitors identi-
ﬁed 13 distinct agents in four categories (b-blockers, other anti-
hypertensives, anti-inﬂammatory antibiotics and statins).57 Pooled
observational cohort studies suggested that b-blockers may reduce
the growth rate of AAA but randomised trials did not support this
observation.57–59 The evidence for statins meanwhile, is only from
potentially biased cohort studies.60,61 It will be challenging to
design trials to assess the role of statin therapy in expansion inhi-
bition as AAA, coronary artery disease and peripheral vascular
disease share common risk factors, so many patients have ﬁrm
indications for statin use. However, with the advent of AAA
screening programmes, such trials would be valuable.
6. Use of statins in other surgical patients
6.1. Patients with sepsis
A recent systematic review identiﬁed 20 studies, mainly retro-
spective, of statins use in sepsis or other infections.62 The studies
were so heterogeneous and the endpoints so diverse that
a combined meta-analysis was not attempted by the authors.
Within the studies included we identiﬁed eight studies poten-
tially relevant to surgical practice.63–70 Six out of seven of the
studies examining the risk of sepsis as the main outcome identiﬁed
decreased odds of sepsis and mortality with pre-hospital statin
use.62 In the last retrospective study we identiﬁed, the authors
postulated whether the anti-inﬂammatory and anti-coagulant
effects of statins made any difference to post-operative wound
complications.70 The study included 10,782 patients undergoing
inguinal or ventral herniorrhaphy and found that whilst statins had
no effect on the risk of wound infection or delayed wound healing,
they were associated with an increased rate of local post-operative
bleeding (p¼ 0.01) although this became of borderline signiﬁcance
after the type of hernia, age, smoking habits, diabetes status, and
body mass index were taken into account (p¼ 0.04).70
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too early to look forward to a trial with mortality from sepsis as an
endpoint.71 However, we identiﬁed ﬁve ongoing randomised trials
looking at the use of statins in sepsis which are relevant from
a surgical standpoint.72–76 Most are investigating safety and levels
of inﬂammatory cytokines as well as secondary endpoints such as
length of stay and time to shock reversal in patients with sepsis,
with one using rosuvastatin in patients with a conﬁrmed diagnosis
of ‘broad peritonitis’ post-surgery.76 The results are awaited with
interest.
6.2. Peritonitis and post-operative adhesion prevention
Leukocyte function antigen-1 (LFA-1) has an important role in
inﬂammation.77 Statins allosterically bind and inhibit LFA-1. Minor
alterations in statin chemistry to optimise LFA-1 binding resulted in
potent, selective and orally active LFA-1 inhibitors which inhibited
neutrophil migration and peritoneal inﬂammation murine perito-
nitis models.78 LFA-1 inhibitors reduce disease burden in patients
with plaque psoriasis, another inﬂammatory process.77 In rat
models of laparotomy-induced adhesions, intra-peritoneal lova-
statin and atorvastatin reduced adhesions by 26% and 58%,
respectively (p< 0.05), possibly via effects on tPA and PAI-1
levels.79 These are early studies and to our knowledge no studies of
statins or selective LFA-1 inhibitors have taken place in patients
with peritonitis.
6.3. Subarachnoid haemorrhage
In rats, statins suppress cerebral aneurysm progression.80 There
has been considerable interest in the ability of statins to prevent
vasospasm and cerebral ischaemia after subarachnoid haemor-
rhage (SAH). The vasospasticmechanism is unclear butmay include
leukocyte–endothelial interactions including LFA-181 and oxy-
haemoglobin induced NO inhibition.82 As discussed previously,
statins bind and inhibit LFA-178 and prolong NOS activity.5
A meta-analysis found statins reduced SAH induced vasospasm
(RR¼ 0.73; 95% CI: 0.54–0.99), delayed ischaemic deﬁcits
(RR¼ 0.38; 95% CI: 0.17–0.83), and mortality (RR¼ 0.22; 95% CI:
0.06–0.82).83 For these outcomes, NNT of 6.25, 5, and 6.7 applied,
respectively.83 At 6 month follow-up, SAH patients treated with 14
days of pravastatin after SAH showed a 73% decrease (p¼ 0.041) in
the composite ‘unfavourable outcomes’ endpoint.84 Subgroup
analysis of statin treated patients who developed vasospasm
showed they had lower LDL-C reductions, suggesting both choles-
terol-dependent and -independent mechanisms are involved.85 A
newmulticentre randomised trial of simvastatin in SAH is currently
recruiting and is expected to report in 2011.86
7. Conclusions
Statins are safe and well tolerated87 and have a variety of
surgically useful pleiotropic effects beside cholesterol-lowering.
Whilst ‘proof of concept’ studies showing other pleiotropic effects
of statins in various situations are welcomed, these must be backed
up by robust randomised trials in appropriate patient groups to
validate efﬁcacy and safety before clinical recommendations about
statin use can be made.
Research into perioperative statin use in many types of vascular
surgery is advanced and such patients should be commenced on
a statin pre-operatively, primarily due to being a population at high
risk of cardiovascular events and this should be continued life-long.
There is no conclusive data as yet on the acute use of statins peri-
operatively for other types of surgery in the low cardiovascular risk
population and we do not know if further acute administration ofstatins in existing users improves outcomes. Existing statin users
should not discontinue their medication in the perioperative period
because of potential for rebound cardiovascular events. Further
studies need to clarify exact dosage regimes and timings of
administration of statins for perioperative patients. Additionally,
the results of multicentre randomised trials looking at statin use in
patients with sepsis and SAH are also awaited to validate a large
body of retrospective data regarding other clinically signiﬁcant
pleiotropic effects in surgical practice.Conﬂict of interest
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